| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5247 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2746 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1648 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1321 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 732 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 580 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 328 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 268 | 2021 |
| Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: The PROLUNG phase 2 randomized … O Arrieta, F Barrón, LA Ramírez-Tirado, ZL Zatarain-Barrón, AF Cardona, ... JAMA oncology 6 (6), 856-864, 2020 | 122 | 2020 |
| Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination K Hillson, SC Clemens, SA Madhi, M Voysey, AJ Pollard, AM Minassian The Lancet 398 (10312), 1683-1684, 2021 | 70 | 2021 |
| Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components S Fedosyuk, T Merritt, MP Peralta-Alvarez, SJ Morris, A Lam, N Laroudie, ... Vaccine 37 (47), 6951-6961, 2019 | 35 | 2019 |
| Cancer immunotherapy-associated hypophysitis F Castillero, O Castillo-Fernández, G Jiménez-Jiménez, J Fallas-Ramírez, ... Future oncology 15 (27), 3159-3169, 2019 | 29 | 2019 |
| Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222) A Flaxman, N Marchevsky, D Jenkin, J Aboagye, P Aley, B Angus Available at SSRN 3873839, 2021 | 15 | 2021 |
| Induction of functional specific antibodies, igG-secreting plasmablasts and memory B cells following BCG vaccination J Bitencourt, MP Peralta-Álvarez, M Wilkie, A Jacobs, D Wright, ... Frontiers in immunology 12, 798207, 2022 | 14 | 2022 |
| Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries AF Cardona, O Arrieta, A Ruiz-Patiño, C Sotelo, N Zamudio-Molano, ... Therapeutic Advances in Respiratory Disease 14, 1753466620938553, 2020 | 14 | 2020 |
| The use of immunotherapy for the treatment of tuberculosis O Ramos-Espinosa, L Islas-Weinstein, MP Peralta-Álvarez, ... Expert Review of Respiratory Medicine 12 (5), 427-440, 2018 | 13 | 2018 |
| Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (6), 1113, 2021 | 7 | 2021 |
| Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination J Bitencourt, M Wilkie, MPP Alvarez, A Jacobs, D Wright, SA Harris, ... bioRxiv, 2021.02. 18.431837, 2021 | 3 | 2021 |
| Correlates of protection from tuberculosis MPP Alvarez, JL Marshall, R Tanner Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges …, 2023 | 2 | 2023 |
| Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a … I Satti, JL Marshall, SA Harris, R Wittenberg, R Tanner, RL Ramon, ... The Lancet Infectious Diseases, 2024 | 1 | 2024 |
Oscar ArrietaHead of the Thoracic Oncology Unit, Instituto Nacional de Cancerología de MexicoDirección de correo verificada de unam.mx
